Foreign ownership of Celltrion Inc. rose during the first half of the year, driven by the company's robust earnings performance and intensified investor relations activities targeting overseas capital.
The increase in foreign stake reflects growing confidence in the biopharmaceutical firm's operational trajectory.
Celltrion shares climbed in Seoul trading as the company reported record second-quarter sales alongside a notable improvement in profitability.
Celltrion shares climbed in Seoul trading as the company reported record second-quarter sales alongside a notable improvement in profitability.
The results signal a strengthening operational position for the firm, which has been a key beneficiary of the global biosimilar market expansion.
The rise in foreign ownership comes as Celltrion continues to expand its global footprint and diversify its product portfolio.
The company's efforts to engage with international investors have paid off, with overseas funds increasing their positions in the stock.
This trend is likely to continue as Celltrion delivers on its growth strategy and maintains its competitive edge in the biosimilar market.
Investors will be watching for further updates on Celltrion's pipeline development and commercialization efforts.